Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 14/20 | 0.45 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.45 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251951 | 0.93 | TNK2 (0.49) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL26820365 | 0.93 | TNK2 (0.49) | TNK2FGFR2IGF1RFGFR1 | |
| Hydrochloric Acid SCHEMBL26661660 | 0.91 | TNK2 (0.48) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL398874 | 0.86 | FGFR2 (0.57) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL14637195 | 0.85 | FGFR2 (0.45) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL14637193 | 0.85 | FGFR2 (0.45) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL1129345 | 0.85 | TNK2 (0.56) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL21852337 | 0.83 | IGF1R (0.49) | TNK2FGFR2IGF1R | |
| SCHEMBL4316054 | 0.78 | TNK2 (0.48) | TNK2FGFR2IGF1RFGFR1 | |
| SCHEMBL17894991 | 0.78 | TNK2 (0.49) | TNK2FGFR2IGF1RFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11512085-B2 | Heteroaryl compound having drug activity | SHANGHAI DUDE MEDICAL TECHNOLOGY CO., LTD (CN) | 2022-11-29 | — | — | US | disclosed |
| EP-3643716-B1 | HETEROARYL COMPOUND HAVING PHARMACEUTICAL ACTIVITY | SHANGHAI DUDE MEDICAL TECH CO LTD (CN) | 2022-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11512085-B2 | Heteroaryl compound having drug activity | BTK, LYN, LCK | TNK2 261/4885FGFR2 2198/4885IGF1R 751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.